Contineum Therapeutics Class A Common Stock Statistics
Share Statistics
Contineum Therapeutics Class A Common Stock has 25.78M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 25.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 42 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 983.61K, so 3.82% of the outstanding shares have been sold short.
| Short Interest | 983.61K |
| Short % of Shares Out | 3.82% |
| Short % of Float | 5.17% |
| Short Ratio (days to cover) | 13.3 |
Valuation Ratios
The PE ratio is 11.3 and the forward PE ratio is -10.67.
| PE Ratio | 11.3 |
| Forward PE | -10.67 |
| PS Ratio | 5.14 |
| Forward PS | 6.6 |
| PB Ratio | -3.78 |
| P/FCF Ratio | 13.56 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Contineum Therapeutics Inc. Class A Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.29, with a Debt / Equity ratio of -2.84.
| Current Ratio | 23.29 |
| Quick Ratio | 23.29 |
| Debt / Equity | -2.84 |
| Total Debt / Capitalization | 154.49 |
| Cash Flow / Debt | 0.1 |
| Interest Coverage | 77.29 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is 12.59%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | 0.17% |
| Return on Capital (ROIC) | 12.59% |
| Revenue Per Employee | 1.61M |
| Profits Per Employee | 732.90K |
| Employee Count | 31 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 450.00K |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Contineum Therapeutics Class A Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 15.05 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 32.09 |
| Average Volume (20 Days) | 97.75K |
Income Statement
In the last 12 months, Contineum Therapeutics Class A Common Stock had revenue of 50.00M and earned 22.72M in profits. Earnings per share was 1.36.
| Revenue | 50.00M |
| Gross Profit | 50.00M |
| Operating Income | 16.08M |
| Net Income | 22.72M |
| EBITDA | 23.57M |
| EBIT | 16.08M |
| Earnings Per Share (EPS) | 1.36 |
Balance Sheet
The company has 15.53M in cash and 193.19M in debt, giving a net cash position of -177.67M.
| Cash & Cash Equivalents | 15.53M |
| Total Debt | 193.19M |
| Net Cash | -177.67M |
| Retained Earnings | -75.14M |
| Total Assets | 216.03M |
| Working Capital | 209.34M |
Cash Flow
In the last 12 months, operating cash flow was 19.35M and capital expenditures -414.00K, giving a free cash flow of 18.93M.
| Operating Cash Flow | 19.35M |
| Capital Expenditures | -414.00K |
| Free Cash Flow | 18.93M |
| FCF Per Share | 1.14 |
Margins
Gross margin is 100%, with operating and profit margins of 32.15% and 45.44%.
| Gross Margin | 100% |
| Operating Margin | 32.15% |
| Pretax Margin | 46.34% |
| Profit Margin | 45.44% |
| EBITDA Margin | 47.15% |
| EBIT Margin | 32.15% |
| FCF Margin | 37.87% |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 10.61% |
| FCF Yield | 5.73% |
Analyst Forecast
The average price target for CTNM is $30, which is 134% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 134% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 38.31 |
| Piotroski F-Score | 2 |